Summary
Seventeen children and two adolescents, aged 6 months to 20 9/12 years, with poor risk leukemia were treated with a total of 38 sequential high-dose ARA-C-Asparaginase courses (HIDAC-ASNase). Each course was followed by profound myelosuppression. Fever occurred in 13.2% and infectious complications in 7.9% of courses. Other side effects were vomiting (81.6%), drug fever (55.3%), mucositis and diarrhoea (28.9%), mild hepatotoxicity (26.3%), exanthemas (18.4%), conjunctivitis (15.8%), local ASNasehypersensitivity (7.9%), athropathy (5.3%). One patient developed generalized seizures followed by coma and death. The possible association between ARA-C, the CNS symptoms and death could neither be demonstrated nor excluded. Except for the possible ARA-C related CNS toxicity, toxic effects were reversible. We consider this treatment a tolerable chemotherapeutic contribution in childhood.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amadori S, Papa G, Avvisati G, Fenu S, Monarca B, Petti MC, Pulsoni A, Mandelli F (1984) Sequential combination of high dose ARA-C (HIDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma. Leuk Res 8 (4): 729–735
Capizzi RL, Cheng Y-C (1982) Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia. Med Pediatr Oncol (Suppl) 1: 221–226
Capizzi RL, Poole M, Cooper MR, Richard F, Stuart JJ, Jackson DV, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D (1984) Treatment of poor risk acute leukemia with sequential high-dose ARA-C and Asparaginase. Blood 63: 694–700
Chu, MY, Fischer GA (1965) Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14: 333–341
Drewinko B, Ho DHW, Barranco SC (1972) The effects of arabinosylcytosine on cultured human lymphoma cells. Cancer Res 32: 2737–2742
Herzig RH; Wolff SN, Lazarus HM, Philips GL, Karanes C, Herzig GP (1983) High-dose cytotosine arabinoside therapy for refractory leukemia. Blood 62: 361–369
Jimenez E, Buchanan GR, Stone MJ (1985) Sequential high-dose ARA-C and Asparaginase in refractory childhood leukemia. Proc Am Soc Clin Oncol 4: 156C-605 (Abstr)
Lazarus HM, Herzig RH, Herzig GP, Philips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48: 2577–2582
Rohatiner A, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA (1984) High-dose cytosine arabinoside: response to therapy in acute leukemia and non-Hodgkins lymphoma. Cancer Chemother Pharmacol 12: 90–93
Rudnik SA, Cadmann EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S (1979) High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44: 1189–1193
Salinsky MC, Levine RL, Aubuchon JP, Schutta HS (1983) Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer 51: 426–429
Schwartz SA, Morgenstern B, Capizzi RL (1982) Schedule dependent synergy and antagonism between high dose cytosine arabinoside and L-asparaginase in the L 5178Y murine leukemia. Cancer Res 42: 2191–2197
Wells R, Devney R, Feusner J (1984) High dose (HD) cytosine arabinoside (CA)/asparaginase (ASP) in advanced childhood leukemia. Proc Am Soc Clin Oncol 3: C-733
Willemze R, Zwaan FE, Keunung JJ, Colpin G (1982) Treatment of refractory acute leukemia with high dose cytosine arabinoside (letter) Br J Haematol 51: 497–498
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grümayer, E.R., Schmidmeier, W., Panzer, S. et al. Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia. Blut 53, 309–314 (1986). https://doi.org/10.1007/BF00320890
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320890